Rhuto India Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 15-05-2024
- Paid Up Capital ₹ 0.10 M
as on 15-05-2024
- Company Age 15 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 M
as on 15-05-2024
- Revenue -5.36%
(FY 2022)
- Profit -8.49%
(FY 2022)
- Ebitda -2.22%
(FY 2022)
- Net Worth 15.35%
(FY 2022)
- Total Assets 9.93%
(FY 2022)
About Rhuto India Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.20 M.
Sudhir Sharma and Sudha Sharma serve as directors at the Company.
- CIN/LLPIN
U24297DL2009PTC188856
- Company No.
188856
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Rhuto India Pharmaceuticals Private Limited offer?
Rhuto India Pharmaceuticals Private Limited offers a wide range of products and services, including Cosmetics, Lip Cosmetics, Ayurvedic, Herbal Oils and Cosmetics, Charcoal Soap, Herbal Cosmetics, Hand Sanitizers & Personal Hygiene, Bath Tools, Bath Soaps, Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics.
Who are the key members and board of directors at Rhuto India Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sudha Sharma  | Director | 26-Mar-2009 | Current |
| Sudhir Sharma | Director | 26-Mar-2009 | Current |
Financial Performance of Rhuto India Pharmaceuticals.
Rhuto India Pharmaceuticals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 5.36% decrease. The company also saw a slight decrease in profitability, with a 8.49% decrease in profit. The company's net worth Soared by an impressive increase of 15.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rhuto India Pharmaceuticals?
In 2020, Rhuto India Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 11 Apr 2019 | ₹0.40 M | Open |
Canara Bank Creation Date: 29 Mar 2017 | ₹0.80 M | Open |
How Many Employees Work at Rhuto India Pharmaceuticals?
Unlock and access historical data on people associated with Rhuto India Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rhuto India Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rhuto India Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
